Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Xiamen Amoytop Biotech Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Xiamen Amoytop Biotech has been growing earnings at an average annual rate of 46%, while the Biotechs industry saw earnings growing at 3.1% annually. Revenues have been growing at an average rate of 27.6% per year. Xiamen Amoytop Biotech's return on equity is 32.7%, and it has net margins of 27.6%.
Anahtar bilgiler
46.0%
Kazanç büyüme oranı
45.4%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 11.3% |
| Gelir büyüme oranı | 27.6% |
| Özkaynak getirisi | 32.7% |
| Net Marj | 27.6% |
| Sonraki Kazanç Güncellemesi | 25 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 26% Jump Shows Its Popularity With Investors
Sep 19
Investors Appear Satisfied With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Prospects As Shares Rocket 26%
Sep 19Is There An Opportunity With Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) 50% Undervaluation?
Jun 12Xiamen Amoytop Biotech (SHSE:688278) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 04Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Share Price Could Signal Some Risk
Mar 25Gelir ve Gider Dağılımı
Xiamen Amoytop Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 2,387 | 658 | 1,179 | 265 |
| 31 Mar 24 | 2,226 | 600 | 1,126 | 234 |
| 31 Dec 23 | 2,100 | 555 | 1,058 | 229 |
| 30 Sep 23 | 1,843 | 456 | 951 | 190 |
| 30 Jun 23 | 1,716 | 356 | 921 | 174 |
| 31 Mar 23 | 1,601 | 314 | 867 | 166 |
| 31 Dec 22 | 1,527 | 287 | 840 | 149 |
| 30 Sep 22 | 1,466 | 254 | 852 | 124 |
| 30 Jun 22 | 1,378 | 243 | 832 | 93 |
| 31 Mar 22 | 1,262 | 204 | 772 | 83 |
| 31 Dec 21 | 1,132 | 181 | 698 | 80 |
| 30 Sep 21 | 1,043 | 168 | 629 | 86 |
| 30 Jun 21 | 904 | 142 | 552 | 79 |
| 31 Mar 21 | 822 | 128 | 506 | 76 |
| 31 Dec 20 | 794 | 117 | 503 | 74 |
| 30 Sep 20 | 762 | 98 | 495 | 57 |
| 30 Jun 20 | 771 | 95 | 495 | 57 |
| 31 Mar 20 | 771 | 86 | 505 | 52 |
| 31 Dec 19 | 730 | 64 | 485 | 50 |
| 30 Sep 19 | 665 | 58 | 441 | 50 |
| 31 Dec 18 | 448 | 16 | 319 | 38 |
| 31 Dec 17 | 323 | 5 | 255 | 18 |
| 31 Dec 16 | 280 | 29 | 203 | 9 |
Kaliteli Kazançlar: 688278 has a high level of non-cash earnings.
Büyüyen Kar Marjı: 688278's current net profit margins (27.6%) are higher than last year (20.7%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 688278's earnings have grown significantly by 46% per year over the past 5 years.
Büyüme Hızlandırma: 688278's earnings growth over the past year (85%) exceeds its 5-year average (46% per year).
Kazançlar vs. Sektör: 688278 earnings growth over the past year (85%) exceeded the Biotechs industry 10.1%.
Özkaynak Getirisi
Yüksek ROE: 688278's Return on Equity (32.7%) is considered high.